Invenra

Invenra is focused on developing the next generation of best-in-class biologics, with an emphasis on multispecific antibodies and their derivatives. Invenra’s proprietary technologies combine our highly developable B-Body™ bispecific platform with high throughput functional screening, enabling the optimization of unprecedented numbers of bispecific antibodies in phenotypic assays. Invenra has a pipeline of immuno-oncology bispecific antibodies that are currently in preclinical studies.